Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)
Updated: December 20, 2025 Gilead Sciences, Inc. (NASDAQ: GILD) heads into the weekend with fresh policy headlines, a high-profile pricing agreement tied to the Trump administration’s TrumpRx initiative, and renewed attention on the company’s next-generation HIV portfolio. The combination has